25Oct 2024
Peanut Allergy Oral Immunotherapy Safe in Primary Care

Peanut Allergy Oral Immunotherapy Safe in Primary Care

The retrospective study assessed the safety and adherence of early oral immunotherapy for peanut allergy (P-EOIT) in a primary care setting. Sixty-nine children under 36 months in New Brunswick, Canada, participated from 2016 to 2020. All reached the maintenance dose of 300 mg of peanut protein over a median of 29 weeks, and 95.7% continued regular peanut protein ingestion after one year. Only one patient required an emergency department visit and epinephrine during the dose escalation phase (1.4%), with no incidents during the first year of maintenance. The findings suggest that P-EOIT in primary care is safe and associated with high patient adherence.

  • #dermatology

Like

Save

Share